You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CDK 4/6 pathway

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors Trial in Seoul (abemaciclib+paclitaxel)

Active, not recruiting
  • Tumors
  • Seoul, Korea, Republic of
    Severance Hospital
May 30, 2022

Breast Cancer Trial (Ribociclib)

No longer available
  • Breast Cancer
  • (no location specified)
Feb 15, 2022

CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Different treatment regimens following progression on CDK4/6 inhibitors.
  • (no location specified)
Sep 5, 2023

Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality

Recruiting
  • Breast Cancer Stage IV
  • comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
  • Mansoura, Dakahlia, Egypt
    Oncology center mansoura university
Jan 1, 2023

Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life Trial in Worldwide (CDK 4/6 inhibitors, Endocrine therapy)

Not yet recruiting
  • Metastatic Breast Cancer
  • +4 more
  • CDK 4/6 inhibitors
  • Endocrine therapy
  • Helsinki, Finland
  • +11 more
Sep 19, 2023

Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

Recruiting
  • Neurofibromatosis 1
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Cancer Trial in Boston (Abemaciclib)

Recruiting
  • Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 9, 2023

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Chordoma Trial in Essen, Heidelberg, Ulm (Palbociclib)

Recruiting
  • Chordoma
  • Essen, Germany
  • +2 more
Dec 6, 2021

Breast Cancer Trial in Boston, Danvers (Ribociclib, Endocrine therapy)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

Recruiting
  • Locally Advanced Breast Cancer
  • Hormone Receptor Positive，HER2-negative Breast Cancer
  • Jinan, Shandong, China
    Breast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023

Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)

Recruiting
  • Breast Cancer
  • Endocrine Therapy and a CDK 4/6 inhibitor
  • Baltimore, Maryland
    Johns Hopkins University
Jul 18, 2022

Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Metastatic Breast Cancer
  • Hospitalet de Llobregat, Barcelona, Spain
  • +6 more
Jan 23, 2023

Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

Recruiting
  • Lung Cancer Squamous Cell
  • +3 more
  • Boston, Massachusetts
  • +2 more
Jan 9, 2023

Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)

Not yet recruiting
  • Advanced Breast Cancer
  • Lebanon, New Hampshire
    Dartmouth Hitchcock Medical Center
Jun 28, 2023

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

Not yet recruiting
  • Advanced HR+ HER2 Negative Breast Carcinoma
  • (CDK)4/6 inhibitor
  • (no location specified)
Sep 27, 2022

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • chidamide combined with fulvestrant
  • (no location specified)
Mar 28, 2023

Learn About Use and Effects of CDK4/6 Inhibitors in Canadian

Active, not recruiting
  • Breast Cancer
    • Kirkland, Quebec, Canada
      Pfizer Canada
    Mar 5, 2023

    Breast Cancer Trial (Abemaciclib, Letrozole)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Nov 14, 2023

    CYP3A4*22 Trial (Palbociclib 125Mg Tab, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG Oral Tablet)

    Not yet recruiting
    • CYP3A4*22
    • Palbociclib 125Mg Tab
    • +2 more
    • (no location specified)
    Jan 10, 2023

    Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

    Not yet recruiting
    • Breast Cancer
    • Marseille, France
      Institut Paoli Calmettes
    Aug 9, 2023

    Breast Cancer Trial (RP-6306, Gemcitabine, Observation)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jan 26, 2023

    Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

    Recruiting
    • Breast Cancer Metastatic Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 26, 2023